Exclusive: UK biotech raises $33.1M to test CF drug that could work on top of standard of care
29 Jan 2024
Phase 2
Enterprise Therapeutics closed a £26 million Series B round to fund a Phase IIa trial of its cystic fibrosis drug, which aims to significantly improve hydration and clear away the mucus that makes breathing difficult for these patients.
Panakes Partners led the round, along with participation from big-name existing investors like Versant Ventures, Novartis Venture Fund and Forbion.
The UK-based biotech plans to dose the first patient with ETD001, its lead drug, in a Phase IIa trial around Easter, CEO John Ford told
Endpoints News
, with the first batch of data set to come out in mid-2025. The trial, which will be conducted in the UK and Europe, has already secured regulatory approval.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.